Because endogenous estrogens directly promote the growth of breast cancer cells, estrogen deprivation either by inhibiting its biosynthesis (aromatase inhibitors) or blocking estrogen-mediated gene transcription (tamoxifen) through its high affinity receptor, the estrogen receptor alpha (ERα), are the primary lines of therapy for breast cancer patients. Here, ESR1 is linked to breast cancer.